Author:
Mingote Laia Ruiz,Namutamba Dorothy,Apina Francis,Barnabas Nomampondo,Contreras Carmen,Elnour Taharqa,Frick Mike Watson,Lee Cynthia,Seaworth Barbara,Shelly Debra,Skipper Natalie,dos Santos Filho Ezio Tavora
Reference9 articles.
1. The use of bedaquiline in the treatment of multidrug resistant tuberculosis expert group meeting report,2013
2. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis;Orenstein;Lancet Infect Dis,2009
3. Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort study;Pietersen;Lancet,2014
4. FDA. Division of Anti-Infective Products. Office of Antimicrobial Products. Briefing package. Sirturo (bedaquiline 100 mg tablets) for the treatment of adults (≥18 years) as part of combination therapy of pulmonary multi-drug resistant tuberculosis (MDRTB). NDA 204-384. Silver Spring: FDA Anti-Infective Drugs Advisory Committee Meeting, 2012. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM329258.pdf (accessed March 24, 2014).
Cited by
16 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献